Skip to content

Phase 2 clinical feasibility study of a new Speaking Valve with a heat- and moisture exchanger (TW) for tracheotomized patients.

Phase 2 clinical feasibility study of a new Speaking Valve with a heat- and moisture exchanger (TW) for tracheotomized patients. - Clinical feasibility of the TW

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON38448
Enrollment
20
Registered
2013-09-04
Start date
2013-09-30
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tracheostomy airway opening Tracheotomy

Interventions

The use of the TW device for a period of 2 weeks, with the option to continue using it until 3 months. After these three months, patients can continue to use the device for a total of one year if th

Sponsors

Atos Medical AB
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • is 18 years or older; • has a tracheostomy; • is spontaneously breathing; • has a cuffless tracheostomy tube; • has a tracheostomy tube with inner- and outer cannula; • currently uses an HME and/or speaking valve.

Exclusion criteria

Exclusion criteria: • is unable to handle or remove the device him/herself when needed, e.g. has decreased level of cognition or reduced mobility of the arms and/or hands; • is mechanically ventilated in any way; • has a tidal volume of less than100 ml; • is suffering from severe aspiration; • is laryngectomized; the device will block the possibility to exhale if speaking mode is unintentionally activated; • has severe upper airway obstruction, this may cause air trapping; • has thick and copious secretions, which might block the device.

Design outcomes

Primary

MeasureTime frame
Exploratory - none. Exploratory parameters are: lungfunction (cough, mucus), breathing, aspiration, speaking, olfaction, use, maintenance and overall statisfaction of the patients.

Secondary

MeasureTime frame
N.A.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)